ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Design Therapeutics Inc

Design Therapeutics Inc (DSGN)

4.03
0.12
(3.07%)
Closed March 29 04:00PM
4.035
0.005
(0.12%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.03
Bid
3.83
Ask
4.24
Volume
220,938
3.82 Day's Range 4.09
1.94 52 Week Range 8.47
Market Cap
Previous Close
3.91
Open
3.90
Last Trade
2
@
4.22
Last Trade Time
Financial Volume
$ 874,828
VWAP
3.9596
Average Volume (3m)
249,887
Shares Outstanding
56,001,992
Dividend Yield
-
PE Ratio
-3.56
Earnings Per Share (EPS)
-1.13
Revenue
-
Net Profit
-63.31M

About Design Therapeutics Inc

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Design Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DSGN. The last closing price for Design Therapeutics was $3.91. Over the last year, Design Therapeutics shares have traded in a share price range of $ 1.94 to $ 8.47.

Design Therapeutics currently has 56,001,992 shares outstanding. The market capitalization of Design Therapeutics is $225.69 million. Design Therapeutics has a price to earnings ratio (PE ratio) of -3.56.

DSGN Latest News

Design Therapeutics Outlines Progress Across GeneTACâ„¢ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in...

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting investors’ caution as they analyze revelations from Nvidia’s artificial intelligence...

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

falseQ30001807120--12-31http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent0001807120dsgn:TwoT...

Form 8-K - Current report

false000180712000018071202023-11-132023-11-13   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.0836.61016949152.954.092.91097002513.64320039CS
41.137.5426621162.934.092.45013118053.25110868CS
121.5361.22.54.092.2452498872.82717993CS
261.5663.15789473682.474.091.963440712.4761246CS
52-1.77-30.51724137935.88.471.944710263.15372941CS
156-33.2491-89.189653183737.2791431.943258178.9218033CS
260-23.97-85.607142857128501.943264759.03039759CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

DSGN Discussion

View Posts

Your Recent History

Delayed Upgrade Clock